S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

OTCMKTS:PKPH - Peak Pharmaceuticals Stock Price, Forecast & News

$0.0089
-0.01 (-40.27 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
$0.01
Now: $0.01
$0.02
50-Day Range
$0.01
MA: $0.01
$0.02
52-Week Range
$0.01
Now: $0.01
$0.12
Volume15,110 shs
Average Volume20,323 shs
Market Capitalization$697,430.70
P/E RatioN/A
Dividend YieldN/A
Beta1.33
Peak Pharmaceuticals, Inc. operates as a bio­pharmaceutical and nutraceutical company in the United States. The company focuses to develop, manufacture, market, and sell medicinal products based on extracts from hemp. It is involved in the development of over-the-counter, THC­free, hemp based products for human market for the prevention and alleviation of symptoms associated with inflammatory and auto-immune diseases. The company was formerly known as Cannabis Therapy Corporation and changed its name to Peak Pharmaceuticals, Inc. in December 2014. Peak Pharmaceuticals, Inc. was incorporated in 2007 and is based in Scottsdale, Arizona.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryCannabis
SectorMedical
Current SymbolOTCMKTS:PKPH
CUSIPN/A
CIKN/A
Phone480-659-6404

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees1
Market Cap$697,430.70
Next Earnings DateN/A
OptionableNot Optionable

Receive PKPH News and Ratings via Email

Sign-up to receive the latest news and ratings for PKPH and its competitors with MarketBeat's FREE daily newsletter.


Peak Pharmaceuticals (OTCMKTS:PKPH) Frequently Asked Questions

What is Peak Pharmaceuticals' stock symbol?

Peak Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PKPH."

Has Peak Pharmaceuticals been receiving favorable news coverage?

News headlines about PKPH stock have been trending positive on Thursday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Peak Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Peak Pharmaceuticals.

Who are some of Peak Pharmaceuticals' key competitors?

What other stocks do shareholders of Peak Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Peak Pharmaceuticals investors own include NVIDIA (NVDA), Canopy Growth (CGC), Cronos Group (CRON), Ekso Bionics (EKSO), Insys Therapeutics (INSY), MannKind (MNKD), Micron Technology (MU), OrganiGram (OGI), Vuzix (VUZI) and Cross Timbers Royalty Trust (CRT).

Who are Peak Pharmaceuticals' key executives?

Peak Pharmaceuticals' management team includes the folowing people:
  • Mr. Neil T. Reithinger, CEO, Pres, CFO, Principal Accounting Officer, Treasurer, Sec. & Director (Age 49)

How do I buy shares of Peak Pharmaceuticals?

Shares of PKPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Peak Pharmaceuticals' stock price today?

One share of PKPH stock can currently be purchased for approximately $0.01.

How big of a company is Peak Pharmaceuticals?

Peak Pharmaceuticals has a market capitalization of $697,430.70. Peak Pharmaceuticals employs 1 workers across the globe.View Additional Information About Peak Pharmaceuticals.

What is Peak Pharmaceuticals' official website?

The official website for Peak Pharmaceuticals is http://www.peakpharma.com/.

How can I contact Peak Pharmaceuticals?

Peak Pharmaceuticals' mailing address is 14201 N. HAYDEN ROAD SUITE A-1, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-659-6404 or via email at [email protected]


MarketBeat Community Rating for Peak Pharmaceuticals (OTCMKTS PKPH)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  141
MarketBeat's community ratings are surveys of what our community members think about Peak Pharmaceuticals and other stocks. Vote "Outperform" if you believe PKPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Featured Article: Gap Down Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel